RxDoctor Payments Data

Terrence Obrien, MD

Ophthalmology · Miami, FLNPI 1861417396

Payments from drug & device makers

$6,607in general payments, 2019–2025

Across 15 payments — averaging $440.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$6K
  • Novartis$286
  • Biotissue Holdings Inc.$269
  • Sun Pharmaceutical Industries Inc.$102
  • Harrow Eye, LLC$69
  • ANI Pharmaceuticals, Inc.$68
  • plus $112 from 4 others

What the payments were for

  • Consulting fees$5,70086%
  • Food & beverage$90714%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,607 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$302,717
Medicare patients
949
Services billed
2,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine87$93,856
Prednisolone Acetate587$33,994
CequaCyclosporine21$16,213
Restasis MultidoseCyclosporine23$15,152
MieboPerfluorohexyloctane/Pf14$13,194
Cyclosporine18$10,965
ZirganGanciclovir16$9,210
CombiganBrimonidine Tartrate/Timolol26$6,858
Difluprednate30$5,289
Loteprednol Etabonate18$4,198
Bromfenac Sodium15$3,568
BromsiteBromfenac Sodium13$2,887
ValacyclovirValacyclovir Hcl56$2,814
Fluorometholone27$2,154
Brimonidine Tartrate60$2,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa, Bromsite$102$19,10034 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$50$4,19818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →